Company Description
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.
The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM.
In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder.
The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.
It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH.
The company was founded in 1901 and is based in Tel Aviv, Israel.
| Country | Israel |
| Founded | 1901 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 37,851 |
| CEO | Richard D. Francis |
Contact Details
Address: Teva Pharmaceutical Industries Limited, 124 Dvora Hanevi'a St. Tel Aviv, L3 6944020 Israel | |
| Phone | 972 (3) 914-8213 |
| Website | tevapharm.com |
Stock Details
| Ticker Symbol | TEVA |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000818686 |
| CUSIP Number | 881624209 |
| ISIN Number | US8816242098 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard D. Francis | President, Chief Executive Officer and Director |
| Eliyahu Sharon Kalif | Executive Vice President and Chief Financial Officer |
| Eric Drape | Executive Vice President of Global Operations |
| Mark Sabag | Executive Vice President of International Markets Commercial |
| Amir Weiss | Senior Vice President and Chief Accounting Officer |
| Ran Meir | Head of Investor Relations |
| Dov Bergwerk | Acting Chief Legal Officer and Corporate Secretary |
| Kathleen Veit | Senior Vice President, Global Compliance and Ethics Officer |
| Vikki Conway | Acting Head of Global Human Resources |
| Kevin C. Mannix | Senior Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2024 | 8-K | Current Report |
| Jun 18, 2024 | 144 | Filing |
| Jun 6, 2024 | 8-K | Current Report |
| May 30, 2024 | SD | Form - SD |
| May 15, 2024 | 8-K | Current Report |
| May 8, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| Apr 18, 2024 | 8-K | Current Report |
| Apr 17, 2024 | UPLOAD | Filing |
| Apr 16, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |